Cannabis Potency Effects on Brain White Matter in Early Phase Psychosis

Launched by NOVA SCOTIA HEALTH AUTHORITY · May 23, 2025

Keywords

ClinConnect Summary

This clinical trial is studying how different strengths of cannabis (potency) affect the brain's white matter in young adults experiencing early phase psychosis. Psychosis can cause symptoms like hallucinations or delusions, and research shows that using cannabis, especially strong varieties, can worsen these symptoms or increase the risk of developing further mental health issues. In this study, researchers will look at three groups of young adults aged 18-25 who use high-potency cannabis, low-potency cannabis, or very little cannabis. They will also test a medication called metformin, which is already used to help manage some side effects of psychosis treatments, to see if it can help with any changes in the brain caused by cannabis use.

Eligible participants must be between 18 and 25 years old and enrolled in the Nova Scotia Early Psychosis Program. If you take part in this study, you'll visit the clinic a few times over six months, fill out questionnaires about your mental health and substance use, and undergo an MRI scan to look at your brain. You'll also take metformin daily for six months. This study is not yet recruiting, but it aims to gather information that could help improve future treatments for young adults struggling with psychosis and cannabis use.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • This study will enroll individuals 18-25 years of age from the Nova Scotia Early Psychosis Program
• Exclusion Criteria:
• • Current stimulant use disorder